Results 221 to 230 of about 229,255 (286)

Global Burden of Disease Due to High Body Mass Index and Projections to 2040: A Study Based on the Global Burden of Disease Study 2019

open access: yesThe International Journal of Health Planning and Management, EarlyView.
ABSTRACT Background The prevalence of high body mass index (BMI) contributes to an increased risk of various diseases. This study aimed to identify global disease burden trends associated with high BMI from 1990 to 2019 and forecasts up to 2040. Methods Using data from the global burden of disease (GBD) 2019 study, we analysed the number and ratio of ...
Eun‐Ji Kim   +4 more
wiley   +1 more source

The excretion of uric acid by the kidney

open access: gold, 1926
Hans Gremels, R. C. de Bodo
openalex   +1 more source

Gout in pregnancy: Obstetric and neonatal outcomes

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 349-355, April 2025.
Abstract Objective The pregnancy, delivery, and neonatal outcomes of pregnancies complicated by gout have yet to be evaluated in a population‐based study. We sought to evaluate the obstetric and neonatal outcomes in pregnant patients with gout using a national population database.
Sam Amar   +3 more
wiley   +1 more source

Isoliquiritigenin Promotes the Repair of High Uric Acid-Induced Vascular Injuries. [PDF]

open access: yesSmart Med
Zhou H   +7 more
europepmc   +1 more source

Diagnostic and prognostic role of thrombospondin‐4 levels in pre‐eclampsia: Association with onset type, severity, and perinatal outcome

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To evaluate the diagnostic and prognostic significance of maternal serum thrombospondin‐4 (TSP‐4) levels in pre‐eclampsia (PE), including comparisons between early‐ and late‐onset disease and between mild and severe cases, and to examine associations with adverse perinatal outcomes. Methods A prospective study was conducted including
Ruken Dayanan   +2 more
wiley   +1 more source

Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report

open access: yesIJU Case Reports, EarlyView.
ABSTRACT Introduction Enfortumab vedotin plus pembrolizumab (EV + P) shows high efficacy in metastatic urothelial carcinoma (mUC), potentially increasing tumor lysis syndrome (TLS) risk. Case Presentation A 64‐year‐old man with mUC underwent surgery and adjuvant nivolumab after neoadjuvant chemotherapy.
Daigo Takemori   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy